Benchmark starts Milestone Scientific at Speculative Buy on pain potential

As previously reported, Benchmark initiated coverage of Milestone Scientific with a Speculative Buy rating and $1.25 price target The STA Single Tooth Anesthesia System and the predecessor C-CLAD devices have been used to deliver more than 92 million dental anesthesia injections since market introduction in early 2007 and now Milestone Scientific is “injecting” growth into its topline by introducing its proprietary, computer-controlled injection system for epidural steroid injections into the pain management market, the analyst tells investors. The value proposition is “attractive for pain management providers,” says the firm, which notes that the company has won coverage from three of the 12 Medicare Administrative Contractors and seeks to obtain coverage at the other nine MACs while also planning to seek reimbursement from private payors.